Gilead settles Biktarvy patent litigation with ViiV for $1.25B upfront + 3% royalty through 2027

GILEAD SCIENCES, INC.

One-time payment of $1.25B to ViiV in Q1 2022; pre-tax charge of $1.25B recorded in Q4 2021.
Ongoing 3% royalty on U.S. sales of Biktarvy and bictegravir products until October 5, 2027.
Settlement resolves all pending and potential claims across U.S. and international jurisdictions.
ViiV grants Gilead a broad worldwide license and covenant not to sue for bictegravir.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.